Virtual Library
Start Your Search
Andres Felipe Cardona Zorrilla
Author of
-
+
IASLC Pre-Conference School of Thoracic Oncology (ID 1)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 10/17/2019, 09:00 - 15:30, Castillo A 1-2
-
+
PC1.03 - Reality of LATAM in Research Production: Frustration and Opportunities (ID 3)
09:00 - 15:30 | Author(s): Andres Felipe Cardona Zorrilla
- Abstract
Abstract not provided
-
+
PC1.07 - How to Become a Translational Physician (ID 7)
09:00 - 15:30 | Author(s): Andres Felipe Cardona Zorrilla
- Abstract
Abstract not provided
-
+
Session 10: Poster Discussion # 2: Metastatic Disease (ID 24)
- Event: LALCA 2019
- Type: Poster Discussion Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2019, 16:15 - 17:15, Castillo A 5-6
-
+
F10.06 - EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms (ID 101)
16:15 - 17:15 | Author(s): Andres Felipe Cardona Zorrilla
- Abstract
Background:
BIM activation is essential for EGFR-TKIs triggered apoptosis in EGFR-mutant Non-small-cell lung cancer (NSCLC). A 2903-bp germline deletion in intron 2 of the BIM gene results in generation of alternatively spliced isoforms that lack the crucial BH3 domain, impairing the apoptotic response to TKIs and conferring NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions (BIMdel).
Method:
A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction (PCR) analysis and direct sequencing of DNA from tumor and peripheral blood cells (PBCs). We also assessed BIM protein expression by immunohistochemistry and BIM mRNA levels by RT-PCR. Clinical characteristics, overall survival (OS), progression-free-survival (PFS), objective response rate (ORR) and treatment-related adverse events were compared in the EGFR-TKIs versus EGFR-TKIs plus Bev groups.
Results:
32 patients were included; 16 of them received EGFR-TKIs and 18 received EGFR-TKIs plus Bev. The addition of Bev resulted in a significantly higher ORR compared with TKIs alone (94% vs. 44%, p=0.0014). Median PFS was longer with the use of the combination compared with TKIs alone (11.1 vs. 7.77?months; p < 0.001). Median OS tended to be longer in the EGFR-TKIs plus Bev group than in TKIs alone (30.9 vs. 25.4?months; p?=?0.06). EGFR-TKIs plus Bev was associated with more grade >3 hematological and thrombotic adverse events. The expression of BIM by immunohistochemistry did not influence PFS and OS, however when stratifying BIM mRNA levels by the median (?2.2 vs. <2.1) allowed to find a prognostic trend in favor of those with higher BIM mRNA levels (32.2 vs. 25.2 months respectively; p = 0.058).
Conclusion:
EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.
-
+
Session 14: Immunotherapy (ID 33)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/19/2019, 14:00 - 15:45, Castillo A 5-6
-
+
S4.04 - Molecular Markers for Immunotherapy (ID 120)
14:00 - 15:45 | Author(s): Andres Felipe Cardona Zorrilla
- Abstract
Abstract not provided
-
+
Session 2: Young Investigators Session & Research Envision (ID 14)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2019, 08:30 - 09:30, Castillo A 5-6
-
+
F2.03 - Be an Author from LATAM: Challenges and Opportunities (ID 71)
08:30 - 09:30 | Author(s): Andres Felipe Cardona Zorrilla
- Abstract
Abstract not provided
